It was announced yesterday that Gauss, a computer vision startup, and Cellex a biotech company have a rapid at-home coronavirus test that achieved sensitivity rates of 94% and specificity rates of 97% compared to the PCR gold standard of lab tests, in a recent clinical trial.
Sensitivity refers to a test’s ability to identify true positive cases, while specificity refers to its ability to find true negative.
Those results are encouraging enough for the companies to move forward for an application for an EUA from the FDA, which is needed to fast track the test for home use.
Yet another example of how the healthtech industry is able to collaborate and rally in collective efforts and align with channel partners for a much needed component of this once in a generation fight we are in.
Full session below.